Drugs / liquid tumor infiltrating lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04924413 | Jul 2021 → Jul 2024 | melanoma | Quanli Gao | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | liquid tumor infiltrating lymphocytes | “liquid tumor infiltrating lymphocytes (L-TIL) combined with tislelizumab” NCT04924413 ↗ |
| Known as | L-TIL | “liquid tumor infiltrating lymphocytes (L-TIL) combined with tislelizumab” NCT04924413 ↗ |
| Modality | Cell therapy | “liquid tumor infiltrating lymphocytes (L-TIL)” NCT04924413 ↗ |
| Route | Other | “for transfusion” NCT04924413 ↗ |